ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2321

Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort

CORAL Mourino Rodriguez1, Jose-Maria Pego-Reigosa2, Iñigo Rúa-Figueroa3, Francisco Rubino4, Iñigo Hernández-Rodríguez5, Raúl Menor-Almagro6, Esther Uriarte Isacelaya7, Eva Tomero Muriel8, TAREK CARLOS SALMAN MONTE9, MARIA IRENE CARRION BARBERA9, Maria Galindo10, Esther Rodriguez almaraz10, Norman Jiménez11, Luis Ines12 and Irene Altabas Gonzalez13, 1Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, 2Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 3Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 4Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 5Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 6Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 7Hospital Universitario de Donostia, Donostia, Spain, 8Rheumatology, Hospital La Princesa, Madrid, Spain, 9Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 10Hospital Universitario 12 de Octubre, Madrid, Spain, 11IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 12Centro Hospitalar e Universitario de Coímbra, Coimbra, Portugal, 13Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain

Meeting: ACR Convergence 2023

Keywords: Disease Activity, Measurement, Patient reported outcomes, registry, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: There is no information available regarding whether the patient’s perception of disease activity aligns with current definitions of DORIS 2021 remission and Lupus Low Disease Activity State (LLDAS), nor whether there is concordance between the patient’s perception and that of the physician.

Aim: To compare the SLE activity perceived by the patient using the Patient Acceptable Symptom State (PASS) question with the global assessment of activity by the physician, as well as with the definitions of LLDAS/DORIS2021.

Methods: Cross-sectional multicenter study of SLE patients from seven Spanish Rheumatology Departments. DORIS 2021 remission definition and LLDAS were applied and the rheumatologists were asked to classify the activity of the disease in 5 different categories: remission, SACQ, low, moderate or high activity. The patients were asked about their clinical SLE condition through the PASS question: “Considering all the different ways your disease is affecting you, if you were to stay in this state for the next few months, do you consider your current state satisfactory?”: PASS yes/PASS no. Statistical analysis: descriptive cross-sectional analysis. Analysis of the level of agreement between the PASS question and categorical classification (remission-low activity/ moderate-high activity) using Cohen’s kappa.

Results: A total of 503 patients were included in the study (92% female, mean age 50.4 years). Table 1 shows in detail the patient´s characteristics at baseline. Of the 503 patient, 386 (77.4%) had an acceptable symptom state according to the PASS question. Mean (±SD) patient global assessment (PtGA) in a scale of 0-100 scale was 29.62 (±24.38) and mean (±SD) physician global assessment (PGA) in a scale of 0-3 was 0.46 (±0.59).A total of 236 (47.6%) patients met DORIS 2021 remission and 289 (59%) met LLDAS. According to the categorical classification of the rheumatologist: 435 (86.8%) patients were in remission or low disease; 56 (11.2%) in moderate activity and 10 (2%) in high activity state (Table 2). Among the patients who answered “yes” to the PASS question, 245 (65.5%) were in LLDAS and 220 (57.9%) were in remission according to the DORIS 2021 criteria. Mean PtGA in these patients was 19.7 (±18) and PGA 0.29 (±0.4). On the other hand, among non-PASS group, 71 (62.8%) patients were not in the LLDAS and 99 (87.6%) did not meet the criteria for DORIS 2021 remission state. Mean PtGA in these patients was 58 (±19) and PGA 1 (±0.7) (Table 3) Overall level of agreement between PASS question and categorical classification by the rheumatologist, was 82% (IC95%: 79.9, 82.9) with a Cohen’s kappa of 0.43.

Conclusion: The majority of SLE patients reported being in an acceptable symptom state according to the PASS question, with similar results reported with the PtGA scale. SLE activity is similarly perceived by the physician perspective valued by the PGA and categorical classification. However, more than a third of patients in the PASS group were not in remission/LLDAS, and approximately 10-35% of the non-PASS group are in a state of remission/LLDAS. It seems that patient perspective is similar to the physician perspective in terms of subjective classification, but some differences are seen in terms of LLDAS and DORIS.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: C. Mourino Rodriguez: None; J. Pego-Reigosa: None; I. Rúa-Figueroa: AstraZeneca, 5, GSK, 1, 6; F. Rubino: None; I. Hernández-Rodríguez: None; R. Menor-Almagro: None; E. Uriarte Isacelaya: None; E. Tomero Muriel: None; T. SALMAN MONTE: None; M. CARRION BARBERA: None; M. Galindo: None; E. Rodriguez almaraz: None; N. Jiménez: None; L. Ines: None; I. Altabas Gonzalez: None.

To cite this abstract in AMA style:

Mourino Rodriguez C, Pego-Reigosa J, Rúa-Figueroa I, Rubino F, Hernández-Rodríguez I, Menor-Almagro R, Uriarte Isacelaya E, Tomero Muriel E, SALMAN MONTE T, CARRION BARBERA M, Galindo M, Rodriguez almaraz E, Jiménez N, Ines L, Altabas Gonzalez I. Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/does-the-perspective-of-sle-patients-match-the-expert-opinion-and-definitions-of-remission-and-low-disease-activity-state-prospective-analysis-of-500-patients-from-a-spanish-multicenter-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-the-perspective-of-sle-patients-match-the-expert-opinion-and-definitions-of-remission-and-low-disease-activity-state-prospective-analysis-of-500-patients-from-a-spanish-multicenter-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology